The third-quarter earnings season came to an end this week for large drugmakers, with AstraZeneca AZN and Bayer BAYRY ...

Click here for a full investment analysis of Cybin Inc., a speculative play on FDA approval for psychedelic-based treatments.

Q3 2024 Earnings Call Transcript November 5, 2024 Operator: Good morning, and welcome to the Otter Tail Corporation’s Third ...

After another slow start, the Tigers' stunted offense took a late lead against the Sooners with the help of the defense.

Six plays and 68 yards later, they cut into the Patriots' momentum with Trevor Lawrence's 6-yard TD pass to rookie Brian Thomas Jr ... fourth touchdown catch of the season. He should go by BTD fr ...

Alzheimer's disease is the most common cause of dementia in the elderly and is characterized by abnormal deposits of amyloid-beta and tau proteins in the brain. This disease has a ...

Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, ...

Topline results from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025; Phase 1 results published in The ...

6 3. Drive routine use of GraftAssure & reorders ... Notably, in October, felzartamab received Breakthrough Therapy Designation (BTD) from FDA for the treatment of late AMR in kidney transplant ...